{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:21:36Z","timestamp":1794057696848,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["21QA1409000"],"award-info":[{"award-number":["21QA1409000"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113331","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T06:13:11Z","timestamp":1656483191000},"page":"113331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Recent advances in lean NAFLD"],"prefix":"10.1016","volume":"153","author":[{"given":"Ruohui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113331_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2022.113331_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2022.113331_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and chronic kidney disease","volume":"17","author":"Marcuccilli","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113331_bib5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib7","first-page":"17295","article-title":"Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin\/AMPK pathway","volume":"8","author":"Li","year":"2015","journal-title":"Int J. Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32047","article-title":"Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD","author":"Vilarinho","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib10","first-page":"389","article-title":"Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease","volume":"74","author":"Vos","year":"2011","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.biopha.2022.113331_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.biopha.2022.113331_bib12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biopha.2022.113331_bib14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","article-title":"Clinical utility of the MAFLD definition","volume":"74","author":"Zheng","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","article-title":"Lean NAFLD: an underrecognized and challenging disorder in medicine","volume":"22","author":"Maier","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.biopha.2022.113331_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2022.113331_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1440-1746.2007.05042.x","article-title":"How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?","volume":"22","author":"Amarapurkar","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41575-021-00433-5","article-title":"What are the clinical settings and outcomes of lean NAFLD?","volume":"18","author":"Ren","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib22","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Kim","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","article-title":"Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy","volume":"62","author":"Wong","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib24","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.5114\/amsad.2019.87122","article-title":"Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population","volume":"4","author":"Li","year":"2019","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"10.1016\/j.biopha.2022.113331_bib25","doi-asserted-by":"crossref","first-page":"17932","DOI":"10.3748\/wjg.v20.i47.17932","article-title":"Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population","volume":"20","author":"Feng","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113331_bib26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity","volume":"15","author":"Fracanzani","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1440-1746.2012.07222.x","article-title":"Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese","volume":"27","author":"Liu","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.15597","article-title":"Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors","author":"Lee","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib29","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2018.11.021","article-title":"Propensity for intra-abdominal and hepatic adiposity varies among ethnic groups","volume":"156","author":"Lim","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113331_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113331_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120562","article-title":"Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients","volume":"7","author":"Denkmayr","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib33","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s10620-019-05926-7","article-title":"Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients","volume":"65","author":"Shao","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.biopha.2022.113331_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15259","article-title":"Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea","author":"Kim","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2022.113331_bib35","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?","author":"Younes","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2022.113331_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(14)63307-2","article-title":"379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease","volume":"146","author":"Cruz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113331_bib38","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","author":"Ahmed","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib39","article-title":"Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease","author":"Kim","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.biopha.2022.113331_bib40","doi-asserted-by":"crossref","first-page":"18273","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113331_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1139\/h06-092","article-title":"Characteristics of metabolically obese normal-weight (MONW) subjects","volume":"32","author":"Conus","year":"2007","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.biopha.2022.113331_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101359","article-title":"Genetics is of the essence to face NAFLD","volume":"9","author":"Meroni","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2022.113331_bib43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2022.113331_bib44","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ajg.2015.235","article-title":"Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy","volume":"110","author":"Wei","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113331_bib45","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113331_bib46","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib47","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","article-title":"Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro","volume":"57","author":"Pirazzi","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib49","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/apt.12609","article-title":"PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome","volume":"39","author":"Shen","year":"2014","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113331_bib50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12072-018-9916-4","article-title":"Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka","volume":"13","author":"Niriella","year":"2019","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biopha.2022.113331_bib51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2022.113331_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.14218\/JCTH.2018.00022","article-title":"The genetics of clinical liver diseases: insight into the TM6SF2 E167K variant","volume":"6","author":"Zhang","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib53","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113331_bib54","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/j.gastro.2016.01.005","article-title":"Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice","volume":"150","author":"Fan","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113331_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacl.2019.02.002","article-title":"Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: a separate phenotype of NAFLD?","volume":"13","author":"Mouzaki","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.biopha.2022.113331_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-387025-4.00004-2","article-title":"Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum","volume":"54","author":"Tarugi","year":"2011","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.biopha.2022.113331_bib58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)39976-4","article-title":"Familial hypobetalipoproteinemia","volume":"34","author":"Linton","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2022.113331_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2010.03.039","article-title":"Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia","volume":"139","author":"Amaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113331_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia","volume":"25","author":"Welty","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.biopha.2022.113331_bib61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/gim.2015.108","article-title":"Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants","volume":"18","author":"Jones","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.prp.2003.11.001","article-title":"Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy","volume":"200","author":"Boldrini","year":"2004","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.biopha.2022.113331_bib63","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17474124.2017.1343144","article-title":"Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD","volume":"11","author":"HH","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2018.09.028","article-title":"The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD","volume":"70","author":"Carter","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091332","article-title":"Rescue of hepatic phospholipid remodeling defectin iPLA2\u03b2-null mice attenuates obese but not non-obese fatty liver","volume":"10","author":"Chamulitrat","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113331_bib66","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s12072-021-10210-w","article-title":"Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice","volume":"15","author":"Yang","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.biopha.2022.113331_bib67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/fcp.12597","article-title":"Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats","volume":"35","author":"Abdelmoneim","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113331_bib68","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcpt.13082","article-title":"Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis","volume":"123","author":"Ipsen","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2022.113331_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113240","article-title":"Effects of a low dose of caffeine alone or as part of a green coffee extract, in a rat dietary model of lean non-alcoholic fatty liver disease without inflammation","volume":"12","author":"Vel\u00e1zquez","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113331_bib70","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.7150\/jca.48495","article-title":"Reduction of polyunsaturated fatty acids with tumor progression in a lean non-alcoholic steatohepatitis-associated hepatocellular carcinoma mouse model","volume":"11","author":"Vlock","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2022.113331_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOG.0b013e32834e7b4b","article-title":"Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression","volume":"28","author":"Corbin","year":"2012","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113331_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e3282fee935","article-title":"Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis","volume":"19","author":"Vance","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.biopha.2022.113331_bib73","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI8814","article-title":"CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis","volume":"105","author":"Leclercq","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.113331_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin is essential for the hepatic fibrogenic response to chronic liver injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib75","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jgh.14122","article-title":"Mouse models of non-alcoholic steatohepatitis: a reflection on recent literature","volume":"33","author":"Haczeyni","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"Rinella","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib77","first-page":"469","article-title":"Metabolic effects of fructose","volume":"9","author":"L\u00ea","year":"2006","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.biopha.2022.113331_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/nu10101502","article-title":"High fat\/high glucose diet induces metabolic syndrome in an experimental rat model","volume":"10","author":"Moreno-Fern\u00e1ndez","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113331_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.shpsc.2017.10.002","article-title":"Epigenetics: a way to bridge the gap between biological fields","volume":"66","author":"Nicoglou","year":"2017","journal-title":"Stud. Hist. Philos. Biol. Biomed. Sci."},{"key":"10.1016\/j.biopha.2022.113331_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030911","article-title":"Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD)","volume":"19","author":"Del Campo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113331_bib81","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3748\/wjg.v25.i23.2863","article-title":"Role of epigenetics in transformation of inflammation into colorectal cancer","volume":"25","author":"Yang","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2022.113331_bib82","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nbt.1685","article-title":"Epigenetic modifications and human disease","volume":"28","author":"Portela","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2022.113331_bib83","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2022.113331_bib85","article-title":"Potential blood DNA methylation biomarker genes for diagnosis of liver fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease","volume":"9","author":"Sun","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2022.113331_bib86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0005-2760(97)00108-2","article-title":"Phosphatidylethanolamine N-methyltransferase from liver","volume":"1348","author":"Vance","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.113331_bib87","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2005.08.026","article-title":"Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet","volume":"44","author":"Igolnikov","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cld.2013.09.017","article-title":"Host genetic variants in obesity-related nonalcoholic fatty liver disease","volume":"18","author":"Mehta","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2022.113331_bib89","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jceh.2019.02.001","article-title":"Whole-exome sequencing identifies a variant in phosphatidylethanolamine n-methyltransferase gene to be associated with lean-nonalcoholic fatty liver disease","volume":"9","author":"Bale","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib90","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jhep.2006.12.012","article-title":"The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population","volume":"46","author":"Dong","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib91","first-page":"1477","article-title":"Phospholipid methylation in mammals: from biochemistry to physiological function","volume":"2014","author":"Vance","year":"1838","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.113331_bib92","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1194\/jlr.M600198-JLR200","article-title":"Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1","volume":"47","author":"Rizki","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2022.113331_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/105221617X15093707969658","article-title":"Updates on dietary models of nonalcoholic fatty liver disease: current studies and insights","volume":"18","author":"Stephenson","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.biopha.2022.113331_bib94","doi-asserted-by":"crossref","first-page":"22403","DOI":"10.1074\/jbc.M110.108514","article-title":"Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity","volume":"285","author":"Jacobs","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113331_bib95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113331_bib96","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1021\/acs.accounts.1c00463","article-title":"Integrative chemical biology approaches to deciphering the histone code: a problem-driven journey","volume":"54","author":"Li","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biopha.2022.113331_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/b456329c-02fa-4055-afb8-2090cec17da6","article-title":"Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma","volume":"8","author":"Rappa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113331_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/biology10070659","article-title":"Phosphorylation within intrinsic disordered region discriminates histone variant macroH2A1 splicing isoforms-macroH2A1.1 and macroH2A1.2","volume":"10","author":"Giallongo","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2022.113331_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/genes8120367","article-title":"Histone MacroH2A1: a chromatin point of intersection between fasting, senescence and cellular regeneration","volume":"8","author":"Lo Re","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2022.113331_bib100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13148-020-00917-2","article-title":"Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)","volume":"12","author":"Buzova","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.biopha.2022.113331_bib101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.113331_bib102","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis, function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2022.113331_bib103","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.113331_bib104","article-title":"Cis regulation within a cluster of viral microRNAs","author":"Vilimova","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2022.113331_bib105","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","article-title":"miRNAs and NAFLD: from pathophysiology to therapy","volume":"68","author":"Gjorgjieva","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2022.113331_bib106","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2018.08.008","article-title":"miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"69","author":"Liu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcmgh.2021.12.003","article-title":"Escherichia fergusonii promotes nonobese nonalcoholic fatty liver disease by interfering with host hepatic lipid metabolism through its own msRNA 23487","volume":"13","author":"Xin","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib108","article-title":"Verification of the nutritional and dietary factors associated with skeletal muscle index in Japanese patients with nonalcoholic fatty liver disease","volume":"2020","author":"Himoto","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib109","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/apt.13889","article-title":"Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113331_bib110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fphys.2020.00605","article-title":"Sedentary and trained older men have distinct circulating exosomal microRNA profiles at baseline and in response to acute exercise","volume":"11","author":"Nair","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2022.113331_bib111","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1249\/MSS.0000000000002661","article-title":"Lifelong exercise in age rats improves skeletal muscle function and microRNA profile","volume":"53","author":"Gao","year":"2021","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.biopha.2022.113331_bib112","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1440-1746.2012.07165.x","article-title":"Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors","volume":"27","author":"Jin","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib113","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib114","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MEG.0000000000001946","article-title":"Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals","volume":"34","author":"Eren","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib115","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2022.113331_bib116","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib117","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib118","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Diabetologia 59 (2016) 1121\u20131140. \u300810.1007\/s00125\u2013016-3902-y\u3009.","DOI":"10.1007\/s00125-016-3902-y"},{"key":"10.1016\/j.biopha.2022.113331_bib119","doi-asserted-by":"crossref","unstructured":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019, Diabetes Care 42 (2019) S34-s45. \u300810.2337\/dc19-S004\u3009.","DOI":"10.2337\/dc19-S004"},{"key":"10.1016\/j.biopha.2022.113331_bib120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.hbpd.2021.06.002","article-title":"The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: a multicenter cross-sectional study in China","volume":"20","author":"Yang","year":"2021","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.biopha.2022.113331_bib121","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113331_bib122","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2022.113331_bib123","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-14-0112","article-title":"External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals","volume":"171","author":"Cuthbertson","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113331_bib124","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113331_bib125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib126","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-021-10147-0","article-title":"The metabolic profiles and body composition of lean metabolic associated fatty liver disease","volume":"15","author":"Cheng","year":"2021","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.biopha.2022.113331_bib127","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.13435","article-title":"The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms","volume":"37","author":"Zelber-Sagi","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2022.113331_bib128","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113331_bib129","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00535-021-01833-9","article-title":"Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review","volume":"56","author":"Kamada","year":"2021","journal-title":"J. Gastroenterol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200720X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200720X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:49:14Z","timestamp":1779968954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222200720X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":129,"alternative-id":["S075333222200720X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113331","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in lean NAFLD","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113331"}}